How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
| Status: | Completed |
|---|---|
| Conditions: | Food Studies, Renal Impairment / Chronic Kidney Disease, Endocrine |
| Therapuetic Areas: | Endocrinology, Nephrology / Urology, Pharmacology / Toxicology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | September 2007 |
| End Date: | August 2012 |
Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease
Patients with chronic kidney disease and end stage renal disease have greater cardiovascular
risk than the general population. Vitamin D analogues have been shown in observational
studies to have mortality benefit for these patients. This study is designed to investigate
doxercalciferol's effect on the vasculature (i.e. endothelial cell function) as a possible
mechanism to explain the mortality benefit.
risk than the general population. Vitamin D analogues have been shown in observational
studies to have mortality benefit for these patients. This study is designed to investigate
doxercalciferol's effect on the vasculature (i.e. endothelial cell function) as a possible
mechanism to explain the mortality benefit.
Inclusion Criteria:
- Stage 5 Chronic Kidney Disease
- Hyperparathyroidism (PTH>300) requiring vitamin D therapy
- Age 18-80 years old
- Ability to provide informed consent
Exclusion Criteria:
- Subjects with neovascularization present, such as neoplasm, active wounds or
significant retinopathy
- Subjects with contraindications or allergy to vitamin D
- Subjects currently on vitamin D therapy or a history of vitamin D therapy in the
previous 60 days
- Serum phosphorus > 6
- Serum calcium > 10.5
- contraindications to nitroglycerin (such as being on sildenafil)
We found this trial at
1
site
Click here to add this to my saved trials
